

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 16<sup>th</sup> May 2025**

**FOI Ref No 28864**

**Requested Information:**

1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.
2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:
  - Admitted as an inpatient
  - Treated in A&E
3. How many patients were treated by the rheumatology department in the past 3 months with the following:
  - Tocilizumab – for any disease
  - Tocilizumab for rheumatoid arthritis (RA) only
  - Tocilizumab for giant cell arteritis (GCA) only
4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?
5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?

**Response:**

1. Yes, Royal Cornwall Hospitals Trust does treat patients for GCA
2. During February to April 2025, the numbers of patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were:
  - Discharged as an inpatient **5**
  - Treated in A&E **7**
3. During February to April 2025, the numbers of patients treated by the rheumatology department who had the following condition (this may not have been the main reason for Tocilizumab being prescribed):

- Tocilizumab – for any disease **105**
- Tocilizumab for rheumatoid arthritis (RA) only **94**
- Tocilizumab for giant cell arteritis (GCA) only **4**

4. During February to April 2025, the numbers of patients treated by the ophthalmology department (for any disease) with Tocilizumab was **0**

5. During February to April 2025, the numbers of patients treated in A&E (for any disease) with Tocilizumab was **0**

**Attachment(s):**

No Attachment(s)

**Date Response sent: 20<sup>th</sup> May 2025**